ESC 2020: Commentary on the PARALLAX Trial — Dr Giuseppe Galati

 

 

Dr Giuseppe Galati (San Raffaele Scientific Institute, Milan, IT) comments on the PARALLAX trial. Dr Galati compares the ESC hotline trial with PARAGON-HF. The PARALLAX study showed potential benefits from sacubitril/valsartan in heart failure with preserved ejection fraction. 

Recorded remotely from Milan, 2020. 

Recording Editors: Natascha Wienand & Tom Green
Editor: Mirjam Boros